An analyst warns to be careful with Vistagen after new anxiety study results.

Sep 23, 2026, 9:34 AM ETResultsRead the original at benzinga.com

Neutral

Vistagen's extension data show long-term safety and symptom gains. The failed primary endpoint and open-label design keep regulatory prospects uncertain.

VTGN · Vistagen Inc.

AI read · Neutral

The AI's read

The extension data increase confidence in long-term safety and show symptom improvements. The main PALISADE-4 study failed its primary goal and the extension was open-label, so regulatory approval remains uncertain.

Get alerts for VTGN

Follow Vistagen Inc. (VTGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VTGN

Free on the App Store and Google Play, or on the web.